에 대한 최신 뉴스 Viking Holdings (NYSE:VIK) 주식

Viking Holdings

Viking Holdings Ltd is a travel company, with a fleet of 92 small, state-of-the-art ships, which view as floating hotels. It offer travel experiences on all seven continents in all three categories of the cruise industry—river, ocean and expedition cruising. The Group defines its products based on the type of cruise offering and language of the cruise service. The River segment provides river cruises outside the United States to English-speaking passengers. The Ocean segment provides ocean cruises to English-speaking passengers. Other includes operating segments that are not individually reportable, consisting of expedition cruises for English-speaking passengers ("Expedition"), Mississippi River cruises for English-speaking passengers, Viking China, which includes cruises for Mandarin.

Analyst Color

Earnings Beats

Price Target

Reiteration

Travel

Analyst Ratings

Movers

Trading Ideas

로얄 캐리비안 크루즈(NYSE:RCL)의 주식은 회사가 긍정적인 4분기 실적을 발표한 후 수요일 1% 이상 상승했다. 이 회사는 이번 흥미로운 실적 시즌 중 분기 실적을 발표했다. 주요 애널리스트 의견은 다음과 같다.

로얄 캐리비안 크루즈가 긍정적인 4분기 실적 기록: &#34;매력적인 장기 전략,&#34; 분석가

Viking Holdings Ltd

Viking Energy Group Inc

Viking Line Abp

Viking Therapeutics Inc

Mizuho analyst Gregg Moskowitz maintains GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) with a Outperform and lowers the price target from $80 to $72.

News

GTLB

Mizuho Maintains Outperform on GitLab, Lowers Price Target to $72

Telsey Advisory Group analyst Cristina Fernandez maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Outperform and maintains $67 price target.

ONON

Telsey Advisory Group Maintains Outperform on On Holding, Maintains $67 Price Target

Barclays analyst Ramsey El-Assal downgrades AvidXchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) from Overweight to Equal-Weight and lowers the price target from $13 to $8.

Downgrades

AVDX

Barclays Downgrades AvidXchange Holdings to Equal-Weight, Lowers Price Target to $8

On Tuesday, BioHarvest Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHST#NASDAQ">BHST</a>) published ‘in vitro' test results for its new olive cell compound, which can reduce fat accumulation in human liver cells.
BioHarvest demonstrated that its novel olive cell compound mitigated fat accumulation in human liver cells, both in a liver steatosis model and in experimental liver fibrosis models.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/12/42431837/exclusive-bioharvest-collaborate-with-tate-lyle-to-develop-proprietary-plant-based-molecules" rel="noreferrer noopener">EXCLUSIVE: BioHarvest Collaborates With Tate &amp; Lyle To Develop Proprietary Plant-Based Molecules</a>
The company attributes the reduction of fat accumulation in liver cells to the high levels of Verbascoside (a plant-derived polyphenol with known anti-inflammatory properties that has been researched for various effects on the liver) in BioHarvest's Olive cell compound.
Based on these results and additional studies to be conducted in 2025, the company expects to begin selling the Olive Cell product in 2026 as a nutraceutical product while continuing to explore the potential of partnering with a pharmaceutical company to provide the olive cell composition via a different regulatory path as part of its contract development and production organization (CDMO) model.
The Olive product will join VINIA as part of the company's portfolio. VINIA, a grape cell product that is high in Piceid Resveratrol, has been clinically shown to significantly dilate arteries, resulting in increased blood flow.
The company recently announced that VINIA had surpassed $50 million in sales, with over 50,000 active subscribers.
BioHarvest plans to support future growth by expanding its production capacity by 4x and building a new 100-ton-per-year production facility, which is expected to be <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/43780365/bioharvest-announces-sales-of-flagship-product-vinia-now-exceed-50-million-usd" rel="noreferrer noopener">operational in late 2026</a>.
Price Action: BHST stock closed at $5.03 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/03/44103926/grocery-giant-albertsons-names-susan-morris-as-new-ceo" target="_blank" rel="noreferrer noopener">Grocery Giant Albertsons Names Susan Morris As New CEO</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

General

BHST

EXCLUSIVE: Botanical Synthesis Tech-Focused BioHarvest's First Synthetic Olive Cells Shows Reduced Fat Accumulation in Liver Cells

<a href="https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions" title="https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions">https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions</a>

Biotech

Johnson & Johnson MedTech Says 'Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform In U.S. To Transform Treatment Of Difficult-To-Cross Calcified Lesions'

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Markets

MARA

MARA Holdings February Bitcoin Product 706 Down From 750 MoM

EXCLUSIVE: BioHarvest Tells Benzinga 'In Vitro Testing of First Lab-Grown Plant-Based Molecules Proves Reduced Fat Accumulation in Liver Cells'

EXCLUSIVE: BioHarvest Tells Benzinga Co. Shows First Synthetic Olive Cells A Capable New Weapon In Fight Against Liver Disease

Parent Company Discusses Strategy to Evolve into a Broader Holding Company with a Focus on Emerging Technologies
NEW YORK, March 4, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/DOMH#NASDAQ">DOMH</a>)&nbsp;(the "Company") today announced that its wholly-owned subsidiary, Dominari Securities LLC ("Dominari"),&nbsp;has received approval for its Continuing Membership Application ("CMA") from the Financial Industry Regulatory Authority ("FINRA"). The Company also provided additional commentary regarding its plans to develop into a broader holding company with a focus on emerging technologies.

DOMH

Dominari Securities Receives FINRA Approval For Its CMA To Expand Operations

WIIM

BeiGene shares are trading higher after the company announced FDA approval of Tevimbra/chemotherapy combination.

On March 3, 2025, iCoreConnect, Inc. (the "Company") entered into warrant cancellation agreements with the holders of warrant to purchase an aggregate of 142,690 shares of common stock. The canceled warrants included anti-dilution provisions that could have led to an increase in the number of warrants and a reduction in the exercise price if new shares were issued by the Company at a lower price.
 &nbsp;

ICCT

iCoreConnect On Mar. 3 Entered Into Warrant Cancellation Agreements With The Holders Of Warrant To Purchase An Aggregate Of 142,690 Shares Of Common Stock

Tiziana Life Sciences, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS. This pivotal step marks a significant advancement in the company's commitment to advance a new treatment approach for Amyotrophic Lateral Sclerosis (ALS) which is supported by the ALS Association.
This IND filing follows the prestigious award of a grant as part of the Hoffman ALS Clinical Trial Awards Program from the ALS Association. Tiziana's intranasal foralumab development programs are now focused on 3 neurodegenerative diseases. ALS, Multiple Sclerosis, and Alzheimer's disease. This grant provides a framework for industry-academia collaboration where new discoveries are translated to clinical studies through innovative research and development.
ALS, also known as Lou Gehrig's disease is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, ultimately leading to muscle weakness and paralysis. ALS is an orphan disease, but its clinical course can be rapid with marked disability even at an early stage. Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe. The disease is always fatal, usually within five years of diagnosis. Despite its devastating impact, treatment options remain limited, highlighting the critical importance of advancing research efforts like those undertaken by Tiziana Life Sciences.
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant. This filing represents a significant achievement for our team and underscores our commitment to addressing the urgent medical needs of ALS patients."
Upon FDA clearance of the IND application, Tiziana plans to commence a 20-patient clinical trial of two doses of Tiziana's novel and patented therapeutic candidate, intranasal foralumab, aimed at evaluating the safety and early-stage parameters of disease improvement in Amyotrophic Lateral Sclerosis (ALS). The company remains dedicated to delivering innovative solutions that can potentially improve outcomes and quality of life for ALS patients worldwide.

TLSA

Tiziana Life Sciences Announces Investigational New Drug Application Submission For Phase 2 Trial Of Intranasal Foralumab In ALS, Supported By ALS Association

- STAR-1 topline results expected by the end of March 2025 -
- Over 30 million acne patients seek treatment in the U.S. each year -
- XYNGARI&#x2122; Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S.&nbsp; and Latin America -

DRMA

Dermata Announced Last Patient Completed Last Visit In XYNGARI Phase 3 STAR-1 Clinical Trial For Acne

New controlled study published in&nbsp;Journal of Nutrition and Dietary Supplements highlights statistically significant reductions in ethanol levels following acute alcohol intake
SCOTTSDALE, Ariz., March 04, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or the "Company"), a wellness and dietary supplement company, today announces the peer-reviewed publication of its groundbreaking randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy of Safety Shot&#xAE; in mitigating the negative effects of alcohol consumption. The study, published in the Journal of Nutrition and Dietary Supplements (Feb 26, 2025, Volume 17, Pages 43-62), demonstrates that Safety Shot&#xAE; statistically significantly reduces blood alcohol concentration (BAC), breath alcohol concentration (BrAC), and hangover symptoms compared to placebo (p &lt; 0.05), and at a remarkably faster rate than the body's natural processes. For the complete article, visit the website at: <a href="https://www.globenewswire.com/Tracker?data=WMrB5FCJ7spqdDFaiGgaOalIPHMLw7p7IOTyw0oAzKQ3WxqFYU0LFhPAP0b-gLXh5BNsAX0_KrPK6x9IyWGObFFPAF2q9v4zTdH-7dHHILiW1TDVIt0rcNZlwME-V15r">https://doi.org/10.2147/NDS.S507571</a>

SHOT

Safety Shot Announces First Peer-Reviewed Publication Of Human Clinical Trial Confirming Rapid Alcohol Reduction And Hangover Prevention Published In The Journal Of Nutrition And Dietary Supplements (Feb 26, 2025, Volume 17, Pages 43-62)

Mizuho analyst Vijay Rakesh maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Outperform and raises the price target from $58 to $68.

MCHP

Mizuho Maintains Outperform on Microchip Technology, Raises Price Target to $68

MASS

908 Devices shares are trading higher after the company reported Q4 financial results and beat its adjusted EPS and revenue estimates.

Management

BCRX

BioCryst Pharmaceuticals' CFO Anthony Doyle Notified The Company Of His Intention To Resign From His Employment With The Company, Effective April 9, 2025

ALZN

Alzamend Neuro Plans To Initiate Phase II Study Of AL001 In Bipolar Disorder, Expected To Commence In Q3

&nbsp;ServiceNow and DXC expand their strategic partnership to combine DXC's industry-leading software and expertise with ServiceNow's AI-enabled platform
ASHBURN, Va. and SANTA CLARA, Calif., March 4, 2025 /PRNewswire/ -&nbsp;DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>), a leading Fortune 500 global technology services provider, today announced new offerings with ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), the AI platform for business transformation, to modernize the insurance industry. As an Elite partner, DXC is combining its <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4374637-1&amp;h=7510929&amp;u=https%3A%2F%2Fdxc.com%2Fus%2Fen%2Fabout-us%2Fawards-and-recognition%2Fdxc-technology-is-recognized-by-everest-group-as-the-leading-life-and-annuities-insurance-technology-provider-is-everest-groups-inaugural-ranking&amp;a=industry-leading+solutions">industry-leading solutions</a>&nbsp;and ServiceNow's AI capabilities&nbsp;and workflows&nbsp;to introduce DXC Assure BPM (Business Process Management) powered by ServiceNow.
Today's insurers are&nbsp;pressured to accelerate growth and innovation, streamline operations, and provide faster, more reliable services to policyholders, but are often constrained by processes and workflows that are complex and highly manual. According to HFS&nbsp;Research, 45% of insurers are already investing in technology-driven alignment of their front, middle, and back offices.
DXC and ServiceNow are uniquely positioned to help insurers drive innovation for greater operational efficiency.&nbsp;&nbsp;Combining DXC's insurance expertise and scale with ServiceNow's single platform and data model, DXC Assure BPM powered by ServiceNow integrates AI, data and workflows to reduce process debt, enhance operational efficiency, and improve customer satisfaction. The solution applies across the entire policy lifecycle and is expected to help reduce up to 40% of operational costs typically spent on manual processing.

DXC And ServiceNow Announce New Offerings To Drive AI-Powered Innovation For The Insurance Industry

Contracts

UAVS

AgEagle Aerial Systems Fulfilled Previously Announced Order For 60 RedEdge-P Multispectral Sensors

Press Releases

Viking Earns Top Honors in U.S. News & World Report's 2025 Best Cruise Line Rankings

Viking Takes Delivery of Newest Ocean Ship

Viking Celebrates Fincantieri Partnership with Naming of Newest Ocean Ship

Viking Recognized in Cruise Critic's 2024 Best in Cruise Awards

Viking Announces 10 New Ocean Itineraries in 2026 and 2027

Viking Launches New "Explorers' Sale"

Viking Appoints Leah Talactac as President

Viking Announces New 2026-2027 World Cruise Itineraries

Viking Receives 2024 North America IPO of the Year Award by International Financing Review

Viking Schedules Conference Call on Fourth Quarter and Full Year 2024 Financial Results

Airbnb

Atour Lifestyle Holdings Limited - American Depositary Shares

Atour Lifestyle Holdings

Booking Holdings

Choice Hotels International, Inc. Common Stock

Choice Hotels Intl

Despegar.com

Expedia Group

Global Business Travel Group, Inc. Class A Common Stock

Global Business Travel

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Gr

Hyatt Hotels Corporation Class A Common Stock

Hyatt Hotels

Hilton Grand Vacations

Hilton Worldwide Holdings Inc. Common Stock

Hilton Worldwide Holdings

H World Group Limited - American Depositary Shares

H World Group

Intercontinental Hotels Group American Depositary Shares (Each representing one Ordinary Share)

InterContinental Hotels

Lindblad Expeditions Holdings Inc. - Common Stock

Lindblad Expeditions

Marriott International - Class A Common Stock

Marriott International

MakeMyTrip

Norwegian Cruise Line Holdings Ltd. Ordinary Shares

Norwegian Cruise Line

Royal Caribbean Cruises Ltd. Common Stock

Royal Caribbean Gr

Sabre

Soho House & Co Inc. Class A Common Stock

Soho House

Trip.com Group Limited - American Depositary Shares

Trip.com Group

Target Hospitality

Travel+Leisure

Marriott Vacations Worldwide Corporation Common Stock

Marriott Vacations

Wyndham Hotels & Resorts, Inc. Common Stock

Wyndham Hotels & Resorts

Loop Capital

Goldman Sachs

JP Morgan

Citigroup

Barclays

로얄 캐리비안 크루즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>)의 주식은 회사가 <a href="https://www.benzinga.com/25/01/43271197/royal-caribbean-cruises-posts-upbeat-earnings-joins-brighthouse-financial-invesco-boeing-and-other-big-stocks-moving-higher-on-tuesday">긍정적인 4분기 실적을 발표한 후</a> 수요일 1% 이상 상승했다.
이 회사는 이번 <a href="https://www.benzinga.com/earnings">흥미로운 실적 시즌</a> 중 분기 실적을 발표했다. 주요 애널리스트 의견은 다음과 같다.
<h1 class="wp-block-heading">골드만삭스의 로얄 캐리비안 크루즈 분석</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/647713f84d196600013124ad/lizzie-dove">애널리스트 리지 도브(Lizzie Dove)</a>는 매수 등급을 유지하면서 목표 주가를 270달러에서 305달러로 상향 조정했다.
로얄 캐리비안 크루즈는 &#8220;인상적인&#8221; 분기 실적을 발표했으며 &#8220;우리가 지적할 것이 아무것도 없다&#8221;고 도브가 언급했다. 경영진은 주당 이익 가이던스를 14달러에서 14.35~14.65달러로 상향 조정했으며, 이는 연료 및 외환 여파 65센트를 제외하면 주당 15달러 이상으로 해석된다고 추가했다.
다가오는 투자자 행사에서 이 회사는 &#8220;휴가 생태계의 더 큰 부분을 차지하기 위한 매력적인 장기 전략을 제시할 것&#8221;이며, 코코케이 멕시코(CocoCay Mexico), 새로운 비치 클럽, 셀러브리티 리버 크루즈 및 새로운 선박이 모두 중요한 요소라고 이 애널리스트가 작성했다.
강과 크루즈 선박의 자본 결과는 &#8220;2026년부터 더 의미 있게 시작될 수 있다&#8221;며, 2025년에 50억 달러의 자본 지출 고점을 넘어서면 가능하다고 덧붙였다.
<h1 class="wp-block-heading">스티펠의 로얄 캐리비안 크루즈 분석</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e84a1b9387cff00014945da/steven-wieczynski">애널리스트 스티븐 비친스키(Steven Wieczynski)</a>는 매수 등급과 목표 주가 310달러를 재확인했다.
로얄 캐리비안 크루즈는 1분기 가이던스를 상향 조정했지만 &#8220;전체 연도에 대해 매우 달성 가능한 범위&#8221;로 안내했다고 비친스키가 말했습니다. 이 회사는 &#8220;웨이브 시즌이 계속 잘 진행될 것으로 보이는 만큼&#8221; 2025년 전체 연도 수익 가이던스를 3월 말 전에 상향 조정할 수 있다고 덧붙였다.
이 회사가 리버 크루즈 시장에 진출하기로 한 결정은 &#8220;흥미롭지만&#8221;, 이 조치가 받는 주목은 &#8220;기회 규모에 비해 너무 과도하다&#8221;고 이 애널리스트가 언급했다. 현재 수요와 지출 비율이 동일하게 유지된다면, 로얄 캐리비안 크루즈는 &#8220;2027년 말경에 주당 약 25달러의 이익을 발생시킬 수 있다&#8221;고 덧붙였다.
<a href="https://www.benzinga.com/analyst-stock-ratings" target="_blank" rel="noopener" data-google-interstitial="false">다른 애널리스트 주식 등급</a>을 확인하세요. 
<h1 class="wp-block-heading">JP모건의 로얄 캐리비안 크루즈 분석</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586bcbd9351b9b0001ab738c/matthew-boss">애널리스트 매튜 보스(Matthew Boss)</a>는 비중 확대 등급과 목표 주가 295달러를 재확인했다.
로얄 캐리비안 크루즈는 4분기 조정된 주당 이익이 1.63달러로, 컨센서스 1.49달러를 초과했다고 보스가 말했다. 전체 연도의 조정 EBITDA와 마진은 거의 코로나19 이전 수준과 일치했다고 덧붙였다.
경영진은 이익 가이던스를 주당 14.35~14.65달러로 상향 조정했으며, 이는 시장의 14.44달러 예상치와 비교된다고 이 애널리스트가 언급했다. &#8220;RCL의 2025년 EPS 초기 가이던스는 14.44달러 예상치보다 +0.5% 높게 설정되었지만, 우리는 연중 또 다른 초과/상향 조정 기회를 볼 수 있다&#8221;고 추가했다.
<h1 class="wp-block-heading">트루이스트 증권의 로얄 캐리비안 크루즈 분석</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59e8ba80efacff0001417468/patrick-scholes">애널리스트 패트릭 스콜스(Patrick Scholes)</a>는 매수 등급과 목표 주가 272달러를 재확인했다.
로얄 캐리비안 크루즈는 2027년에 10척의 선박으로 새로운 셀러브리티 리버 크루즈 브랜드로 리버 크루즈 시장에 진입할 계획이라고 스콜스가 말했다. 그러나 리버 크루즈 부문은 바이킹 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>)가 지배하고 있다고 덧붙였다.
로얄 캐리비안 크루즈가 10척의 선박으로 시장에 진입할 예정이지만, 바이킹은 90척 이상의 선박을 보유하고 있다고 이 애널리스트가 언급했다. &#8220;가격대가 다를 것으로 예상되기 때문에&#8221; 직접 경쟁은 발생할 가능성이 낮다고 덧붙였다. 바이킹은 럭셔리 브랜드로 간주되고 셀러브리티는 &#8220;컨템포러리/중상위 시장&#8221; 브랜드로 분류다.
RCL 주가 변동: 로얄 캐리비안 크루즈의 주가는 수요일 미국 동부 시단 오후 3시22분 1.47% 상승하여 269.15달러에 거래되었다.
사진: Royal Caribbean 제공
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Viking Holdings

뉴스

에 대한 최신 뉴스 Viking Holdings (NYSE:VIK) 주식

수요일, 1월 29, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌